Organon & Co
Change company Symbol lookup
Select an option...
OGN Organon & Co
CPSI Computer Programs and Systems Inc
TKNO Alpha Teknova Inc
BTM Bitcoin Depot Inc
RC Ready Capital Corp
NEOV NeoVolta Inc
SCHL Scholastic Corp
SIDU Sidus Space Inc
MGY Magnolia Oil & Gas Corp
CWBR CohBar Inc
Go

Health Care : Pharmaceuticals | Small Cap Value

Organon & Co. (Organon) is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (Organon Products). Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing, Follistim AQ, and Elonva. The Company’s Biosimilars portfolio spans immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The Company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. It operates its manufacturing facilities in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

Closing Price: $18.26

Day's Change: -0.32 (-1.72%)

Bid: --

Ask: --

B/A Size: --

Day's High: 18.77

Day's Low: 18.22

Volume (Average) Volume: 3,089,088 10-day average volume: 2,849,106: 3,089,088

September 14, 2023
5:12 pm ET	First Real-World Observational Study of the JADA(R) System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG's Obstetrics & Gynecology --PPH is a Significant Cause of Maternal Morbidities in the U.S.(2,3,4,5) --New Exploratory Post-Hoc Analysis Examined the Relationship Between Reported Severe Maternal Morbidity (SMM) Outcomes and Cumulative Blood Loss Prior to JADA Insertion(1) (BusinessWire)
September 05, 2023
10:00 am ET	Organon Bolsters Research & Development Expertise with Two Leadership Appointments Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced the appointment of Juan Camilo Arjona Ferreira, M.D., as Chief Medical Officer (CMO) and Charlotte Owens, M.D., as Head of Medical Affairs and Outcomes...(BusinessWire)
August 08, 2023
8:30 am ET	Organon (OGN) Reports Q2 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Organon (OGN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.(Zacks)
7:50 am ET	Organon (OGN) Q2 Earnings and Revenues Beat Estimates Organon (OGN) delivered earnings and revenue surprises of 35.05% and 3.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?(Zacks)
7:30 am ET	Organon Reports Results for the Second Quarter Ended June 30, 2023 Organon (NYSE: OGN) today announced its results for the second quarter ended June 30, 2023. "During the second quarter of 2023, Organon continued to build on its track record, delivering solid volume growth across all regions and franchises. The...(BusinessWire)
August 01, 2023
7:00 am ET	Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar(Globe Newswire)
July 17, 2023
7:30 am ET	Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023 Organon (NYSE: OGN), a global women's healthcare company will release its second quarter 2023 financial results on August 8, 2023, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. (BusinessWire)
July 05, 2023
8:01 am ET	Dare Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO(TM) (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis(Globe Newswire)
7:40 am ET	Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S. Organon & Co. (OGN) and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move comes after Humira, AbbVie' Inc.'s (ABBV) rheumatoid arthritis drug that is one of the best...(MarketWatch)
6:30 am ET	REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA(TM) (adalimumab-bwwd) in Multiple Presentations Consistent with Originator Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. announced that HADLIMA(TM) (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now available to patients in the United States. Consistent with Humira, HADLIMA is available...(BusinessWire)
July 01, 2023
6:30 am ET	Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA(TM) (adalimumab-bwwd) in Multiple Presentations Consistent with Originator Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA(TM) (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now available to patients in the United States. Consistent with Humira, HADLIMA is...(BusinessWire)
June 29, 2023
7:45 am ET	Organon Publishes 2022 ESG Report Showcasing Progress Toward Global Sustainability Goals NORTHAMPTON, MA / ACCESSWIRE / June 29, 2023 / Organon (NYSE:OGN), a global healthcare company focused on women's health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report. The report highlights the company's progress...(Accesswire)
June 27, 2023
7:30 am ET	Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals Organon (NYSE: OGN), a global healthcare company focused on women's health, today released its 2022-2023 Environmental, Social, and Governance (ESG) Report. The report highlights the company's progress on its comprehensive ESG platform, Her Promise...(BusinessWire)

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and